O-I Glass, Inc., through its subsidiaries, engages in the manufacture and sale of glass containers to food and beverage manufacturers primarily in the Americas, Europe, and internationally. The ...
The MarketWatch News Department was not involved in the creation of this content. Neither study achieved its primary endpoint of reduction in annualized clinical fracture rate compared to placebo ...
LONDON, Dec. 29, 2025 (GLOBE NEWSWIRE) -- Mereo BioPharma Group plc (NASDAQ: MREO) (“Mereo” or the “Company”), a clinical stage biopharmaceutical company focused on rare diseases, today announced ...
NOVATO, Calif., Dec. 29, 2025 (GLOBE NEWSWIRE) -- Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE) today announced results from the Phase 3 Orbit and Cosmic studies for setrusumab (UX143) in Osteogenesis ...
Mereo’s drug candidate for brittle bone disease missed its primary endpoint in a recent phase 2b study, but analysts at Cantor Fitzgerald reckon that may not stop the drug getting approved. Brittle ...
Prolyl 3-hydroxylase 1 (P3H1) is encoded by the LEPRE1 gene, and forms a collagen-modifying complex with cartilage-associated protein (encoded by CRTAP) and cyclophilin B. Hydroxylation of α1 ...
We recently published 10 Stocks on Fire Ahead of 2026. Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE) is one of the best performers on Tuesday. Ultragenyx rebounded by 15.52 percent on Tuesday to close ...
Podcasts Music Commentary Song of the Day From MPR News Music lovers from 89.3 The Current comb through mountains of music to choose the best new, independent, and unreleased songs to share with you ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback